Skip to main content
Frederick Lansigan, MD, Oncology, Lebanon, NH, Dartmouth-Hitchcock Medical Center

FrederickLansiganMD(He/Him)

Oncology • Lebanon, NH

Cutaneous Lymphoma, Hematologic Oncology

Interim Associate Dean of Diversity, Equity, and Inclusion, Associate Professor, Medicine and Dermatology, Geisel School of Medicine at Dartmouth

Join to view full profile

Dr. Lansigan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lansigan's full profile

Already have an account?

Summary

  • Erick Lansigan, MD is an authority on quality improvement and applies this methodology to promoting Diversity, Equity, Inclusion, and Belonging in education, admissions, recruiting, student experience, workforce development, advocacy, and community engagement, as well as clinical research, health systems, and patient care.

Education & Training

  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)
    Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2002 - 2006
  • State University of New York Downstate Medical Center College of Medicine
    State University of New York Downstate Medical Center College of MedicineClass of 2002

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2009 - 2025
  • ME State Medical License
    ME State Medical License 2020 - 2021
  • CT State Medical License
    CT State Medical License 2006 - 2008
  • NY State Medical License
    NY State Medical License 2004 - 2008

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)
    Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
    Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
    Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Diversity Among Oncologists Has Not Kept Pace with the U.S. Population
    Diversity Among Oncologists Has Not Kept Pace with the U.S. PopulationFebruary 17th, 2022
  • Oncology Academic Departments Slowly Becoming More Diverse
    Oncology Academic Departments Slowly Becoming More DiverseDecember 30th, 2021
  • Lenalidomide plus Rituximab: Effective for Older Patients with R/R Indolent NHL
    Lenalidomide plus Rituximab: Effective for Older Patients with R/R Indolent NHLDecember 6th, 2020

Professional Memberships

Hospital Affiliations

Dr. Frederick Lansigan, Dr. Frederick Lansigan, MD, Dr. F Lansigan